Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00048373 · ClinicalTrials.gov registry record · Phase 2
Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL
A Phase 2 study of Histiocytosis, Langerhans-Cell, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00048373: Completed Phase 2 study of Histiocytosis, Langerhans-Cell, sponsored by Baylor College of Medicine.
NCT00048373 is a Phase 2 study of Histiocytosis, Langerhans-Cell that has completed, run by Baylor College of Medicine. The registered enrollment target is 20 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00048373, a Phase 2 study of Histiocytosis, Langerhans-Cell, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn about the response of Langerhans cell histiocytosis (LCH) to Enbrel in patients who have failed to respond to standard therapies. We are also looking specifically at what side effects Enbrel has on patients. We expect to enroll 20 patients on this study and anticipate the subjects active participation to last up to one year.
Conditions Studied
Interventions
- DRUG Etanercept
Study Locations (1)
Texas
- Texas Children's Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2001-10 |
| Est. Completion | 2004-04 |
| Phase | Phase 2 |
What the finished NCT00048373 record still lists
NCT00048373 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Histiocytosis, Langerhans-Cell appearing as the primary indexed condition, and to 1 intervention - of which Etanercept is the first listed.
NCT00048373 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00048373 about?
NCT00048373 is a clinical study titled "Treatment of Resistant Langerhans Cell Histiocytosis With ENBREL". The purpose of this study is to learn about the response of Langerhans cell histiocytosis (LCH) to Enbrel in patients who have failed to respond to standard therapies. We are also looking specifically at what side effects Enbrel has on patients. We expect to enroll 20 patients on this study and anti...
What is the current status of trial NCT00048373?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2001-10. Estimated completion is 2004-04.
What conditions does trial NCT00048373 study?
This clinical trial studies the following conditions: Histiocytosis, Langerhans-Cell.
What interventions are being tested in trial NCT00048373?
The interventions under investigation include: Etanercept (DRUG).
Who is sponsoring clinical trial NCT00048373?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00048373 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Histiocytosis, Langerhans-Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00048373's enrollment target sits among peer trials
20 1805th of 2000 higher than 107 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia